Healthcare

Aroa Biosurgery (ASX:ARX) surged during a session that highlighted growing momentum across the ASX biotech segment, drawing renewed attention to one of the most visible Australian-listed biotech names with a commercial product portfolio. The move reflects both stock-specific factors and broader rotation back into …

Island Pharmaceuticals (ASX:ILA) has reported one of its most productive quarters in recent memory, with the March 2026 update highlighting FDA alignment on galidesivir’s Animal Rule pathway and a A$9 million strategic funding raise. The combination provides Island with a clearer regulatory framework and …

EBR Systems (ASX:EBR) has reached an important regulatory milestone in its Australian commercialisation pathway, securing Priority Review Determination from theTherapeutic Goods Administration(TGA) for its wireless WiSE cardiac resynchronisation therapy (CRT) system. The decision shortens the expected evaluation period from the standard 225 working days …

Firebrick Pharma (ASX:FRE) has positioned 2026 as a defining year for its Nasodine respiratory virus product portfolio, accelerating international commercial expansion across Southeast Asia and other regulator-friendly markets. The company has historically faced a more challenging regulatory environment for nasal sprays in some Western …

ASX health stocks are entering one of the most catalyst-rich windows in recent memory, with multiple Phase 3 readouts and major regulatory inflection points clustered through calendar 2026. The combination provides ASX investors with a structurally interesting window for biotech exposure, particularly relative to …

Renascor Resources (ASX:RNU) has reached one of its more meaningful operational milestones, beginning full-plant commissioning of its purified spherical graphite (PSG) demonstrationFacilityin Adelaide. Construction has been completed and pre-commissioning checks finalised, with the project on budget and on schedule, and processing of graphite using …

Singular Health Group Ltd (ASX:SHG) has reached an important commercial milestone, receiving US$500,000 from Provider Network Solutions (PNS) under its existing US enterprise agreement. The payment confirms the contracted rollout of an additional 500 3DICOM MD platform licences and signals further commercial progress for …